Thursday, Caliper Life Sciences, Inc. (CALP), an instruments, software, and reagents company, reported a wider net loss in the fourth quarter primarily due to significant non-cash charges.
The Hopkinton, Massachusetts-based company's fourth quarter net loss widened to $46.3 million or $0.95 per share from $5.7 million or $0.12 per share in the year-ago period.
Results for the quarter include $45.3 million or $0.93 per share of non-cash goodwill impairment and other restructuring charges.
On a non-GAAP basis, the company posted a net loss of $0.02 per basic share, compared to a net loss of $0.05 per basic share a year earlier.
Quarterly revenues declined 8.8% to $36.7 million from $40.3 million in the comparable period last year. Excluding the effects of product line divestitures and unfavorable effects of foreign currency translation, revenue declined 2% from the year-ago period.
Product revenue declined to $25.5 million from $28.2 million last year, service revenue declined to $8.9 million from $9.5 million, and license fees and contract revenue declined to $2.3 million from $2.6 million in the previous year.
For the full year, the company posted a net loss of $68.3 million or $1.42 per share, compared to net loss of $24.1 million or $0.51 per share in the prior year. Non-GAAP net loss was $0.27 per basic share, compared to a net loss of $0.25 per basic share in the previous year.
Revenues for the year declined to $134.0 million from $140.7 million a year ago.
Looking ahead, the company expects first-quarter revenue in the range of $25.0 to $28.0 million. For the full year 2009, Caliper anticipates organic revenue growth between 4 to 7% over 2008 pro forma revenue of $122.8 million.
CALP is currently trading at $1.03, up $0.09 or 9.57% on the Nasdaq.
For comments and feedback: editorial@rttnews.com